Index
Pharmacological Reviews
Volume 38
1986

Abdel-Latif, A. A. Calcium-mobilizing receptors, polyphosphoinositides, and the generation of second messengers, 227
Acetylcholine, calcium antagonism and calcium entry blockade, 337
Adenohypophysis, calcium antagonism and calcium entry blockers, 360
Adenosine triphosphatase
cellular effects of cannabinoids, 67
effects of cannabinoids (table), 48
Adenylate cyclase
cAMP levels and, effects of cannabinoids (table), 49
effects of cannabinoids, 48
Adrenergic agents, effect on airway secretion, 281
Adrenoceptors, alpha, calcium antagonism and calcium entry blockade, 383
Afferents, neuropharmacology of capsicain, 188
Agurell, Stig, Magnus Haldin, Jan-Erik Lindgren, Agneta Ohlson, Marianne Widman, Hamp Gillespie, and Leo Hollister. Pharmacokinetics and metabolism of Δ9-tetrahydrocannabinol and other cannabinoids with emphasis on man, 21
AIDS, health aspects of cannabis, 3
Airplane flying, health aspects of cannabis, 12
Airway
effects of air pollutants, 279
pharmacology of secretion, 273
surface epithelium, secretory physiology, 278
Alcohol, health aspects of cannabis, 7
Alkalosis, calcium antagonism and calcium entry blockade, 337
Amino acids
helical wheel diagrams, calcitonin (fig.), 308
sequences in calcitonin homologues (fig.), 307
sequences of β-endorphin (fig.), 295
AMP, cyclic
adenylate cyclase and, effects of cannabinoids (table), 49
effect of phosphodiesterase inhibitors, airway secretion, 283
Analgesia
characterization of β-endorphin, 304
health aspects of cannabis, 14
neuropharmacology of capsicain, 183, 187
time courses of effects, β-endorphin (fig.), 305
Anesthesia, neuropharmacology of capsicain, 204
Angina pectoris, calcium antagonism and calcium entry blockade, 389
Anoxia, calcium antagonism and calcium entry blockade, 337
Antiasthmatics, cellular effects of cannabinoids, 68
Anticonvulsants
cannabinoids, 77, 171
cellular effects of cannabinoids, 66
health aspects of cannabis, 15
Antiemetics
cancer chemotherapy patients, health aspects of cannabis, 13
cannabinoid pharmacology, 171
Antiglaucoma agents, cellular effects of cannabinoids, 68
Anti-inflammatory agents, cannabinoid pharmacology, 171
Antinociception, cannabinoid pharmacology, 170
Aorta
calcium entry blockers, 326
differences between rat and rabbit, calcium antagonism, calcium entry blockers (fig.), 330
Arachidonic acid
biosynthesis (fig.), 54
calcium-mobilizing receptors, 251
effects of tissue, AA liberation or prostaglandin release (table), 252
Arrhythmias
calcium antagonists, 388
experimental, 354
Asthma, health aspects of cannabis, 15
Automobile driving, health aspects of cannabis, 12
Bacteria, effect on airway secretion, 279
Basophils, calcium role, 364
Behavior
aggressiveness, cannabinoid pharmacology, 155
cannabinoid pharmacology, 153
effects of cannabinoids (table), 78
hashish use, health aspects of cannabis, 3
lipophilicity of cannabinoids, 63
pharmacology, 156
Benzopyran, compared with THC ring systems (fig.), 82
Bepridil, cardiac tissue effect, 350
Blood plasma
measurement of tetrahydrocannabinol, 23
profile, smoking and injection of THC, 40
Brain
accumulation of cannabis, 11
calcium antagonism and calcium entry blockers, 355
hashish use, health aspects of cannabis, 3
neurotransmitter release, calcium entry blockers, 357
Buck, Stephen H., and Thomas F. Burks. The neuropharmacology of capsicain: Review of some recent observations, 179
Burks, Thomas F. See Buck and Burks, 179
Calcitonin
amino acid sequences in naturally occurring homologues (fig.), 307
CGRP and, characterization of β-endorphin, 306
helical wheel diagrams, amino acid residue side chains (fig.), 308
Calcium
agonist- and depolarization-induced contractions in aorta (table), 331
antagonism and calcium entry blockade, 324
antagonists, clinical applications (table), 389
calcium ionophores and, effect on airway secretion, 283
channel receptor sites (fig.), 376
channels, voltage-dependent, 379
time courses of, β-endorphin (fig.), 305
entry blockers (fig.), 325
in aorta (fig.), 330
mechanism of action, 367
nitrendipine binding (fig.), 371
selectivity, 385

417
Calcium—continued
influx in resistance vessels (table), 339
ion regulation in cell, polyphosphoinositides (fig.), 234
IP$_3$-induced release (table), 246
mobilizing receptors, polyphosphoinositides, generation of second messengers, 227
modulators (table), 325
plasma membrane functions, 241
Calmodulin, calcium antagonism and calcium entry blockade, 382
Cancer, chemotherapy, health aspects of cannabis, 13
Cannabinoid antagonists
design, 57
evaluation of analogs (fig.), 58
receptors, 56
Cannabinoids
cellular effects, 45
compared with steroid structures (fig.), 61
effects on miscellaneous enzymes (table), 51
effects on prostaglandins (table), 53
heterocyclic and aminocarbocyclic structures (fig.), 58
in man (table), 84
mean plasma curve of CBD (fig.), 32
metabolism of CBD and CBN, 39
pharmacokinetics of CBD and CBN in man, 32
pharmacology, 151
smoking and injection (fig.), 33
structure-activity relationships, 75
structure of CBD metabolites (table), 39, 40
tetrahydrocannabinol
effects on activity and rectal temperature, mice (table), 81
pharmacokinetics, emphasis on man, 21
Cannabis, health aspects, 1
Capsaicin
anesthesia and pyrexia, 204
cardiovascular function, 211
chemical structure (fig.), 180
gastrointestinal function, 209
muscle reflexes, 205
neuropharmacology, 179
ocular function, 207
reports of substance P depletion (table), 181
sensory specificity, 217
therapeutic implications, 220
thermoregulation, 200
visceral reflexes, 205
Cardiac tissues
action potentials (fig.), 349
calcium antagonism and calcium entry blockade, 347
Cardiovascular system
cannabinoid pharmacology, 167
neuropharmacology of capsaicin, 211
Cascade, pharmacotherapeutic (table), 390
Cell metabolism, health aspects of cannabis, 5
Central nervous system
capsaicin
neuronal plasticity, 189
neuronal specificity, 216
neuropharmacology, 185
therapeutic implications, 220
Cerebral arteries, calcium antagonism and calcium entry blockade, 332
Chemotherapy, cancer, health aspects of cannabis, 13
Cholinergic agents, effect on airway secretion, 280
Cholinergic systems, cannabinoid pharmacology, 163
Cinnarizine, effect on calcium-evoked contractions (fig.), 326
Coronary artery
calcium antagonism and calcium entry blockade, 334
nifedipine
concentration-effect curves (fig.), 386

INDEX

effect (fig.), 391
Cyclic AMP. See AMP, cyclic

Dewey, William L. Cannabinoid pharmacology, 151
1,2-Diaclyglycerol, inositol 1,4,5-trisphosphate and, synergistic interactions, 254
Diaclyglycerols, protein kinase C, 248
Dibenzopyran, numbering system for metabolites, confusion, monoter-
pene method, 21
Dihydropyridine
binding, chemical properties, 374
dissociation constants in membranes (table), 368
Drugs
blockers, dependence, cannabinoid pharmacology, 160
development, cannabinoids, 77
glossary of chemical names (table), 393
interactions, cannabinoid pharmacology, 165

Endocrine systems, cannabinoid pharmacology, 169

Endocrine tissues, calcium antagonism and calcium entry blockers, 359, 361
Endoplasmic reticulum, IP$_3$-induced calcium release, 246

beta-Endorphin
binding potencies to opiate receptors (table), 300
helical net diagrams (fig.), 297
opiate antagonists (table), 302
physicochemical properties (table), 298
resistance to enzyme activation (table), 299
structural characterization, 291

Enzymes
cellular effects of cannabinoids, 65, 67
effects of cannabinoids (table), 51
inactivation
beta-endorphin, 298
beta-endorphin (table), 299

Epithelium, airway, pharmacology of secretion, 274

Erythrocytes, calcium role, 364

Estradiol, compared with cannabinoid structures (fig.), 61
Exocrine tissues, calcium role, 366
Eye, health aspects of cannabis, 10

Feces, excretion of tetrahydrocannabinol metabolites, 37

Fetus, health aspects of maternal use of cannabis, 4
Flunitrazepam, effect of protein concentration in assay medium, nitren-
dipine binding (fig.), 373

Food intake
cannabinoid pharmacology, 170
neuropharmacology of capsaicin, 215
Gastric mucosa, calcium role, 367
Gastrointestinal tract, neuropharmacology of capsaicin, 209
Gillespie, Hamp. See Agurell et al., 21
Glandular cells, pharmacology of airway secretion, 277
Glucon, health aspects of cannabis, 14
Glucon
amino acid sequences (fig.), 311
characterization of beta-endorphin, 310
helical net diagram (fig.), 311
Godfraind, Theophile, Robert Miller, and Maurice Wibo. Calcium antagonism and calcium entry blockade, 321
GTP-binding, receptors, polyphosphoinositides and second messengers (fig.), 243
Halldin, Magnus. See Agurell et al., 21
Heart
correlation between binding and inotropic effect (table), 378
health aspects of cannabis, 10
noradrenergic transmission, calcium antagonism and calcium entry blockers, 356
Histamine, effect on airway secretion, 284
Hollister, Leo E. Health aspects of cannabis, 1
Hollister, Leo. See Agurell et al., 21
Hormones
amphipathic peptide, characterization of beta-endorphin, 313
beta-endorphin, structural characterization, 291
Hypertension, calcium antagonism and calcium entry blockade, 389
Hypoxia, health aspects of cannabis, 3
Immune response, health aspects of cannabis, 3
Inositol phosphates, extraction and analysis, 236
Inositol 1,4,5-trisphosphate, 1,2-dicylglycerol and, synergistic interactions, 254
Insomnia, health aspects of cannabis, 15
Kidney
juxtaglomerular cells, 362
tubules, calcium entry blockers, 367
Leukotrienes, prostaglandins and, 67
Lidoflazine, treatment of ischemic heart disease, 353
Ligand-receptor binding, neuropharmacology of capsaicin, 190
Lindgren, Jan-Erik. See Agurell et al., 21
Lithium, polyphosphoinositide response, 237
Liver, metabolites of tetrahydrocannabinol (table), 37
Lung
health aspects of cannabis, 10
method of smoking cannabis, metabolism of tetrahydrocannabinol, 23
pharmacology of airway secretion, 273
Lymphocytes, calcium antagonism and calcium entry blockade, 364
Macromolecules, metabolism, effects of cannabinoids, 50
Marijuana
chemical entities, 152
health aspects of cannabis, 15
smoking, health aspects of cannabis, 2
structure-activity relationships, cannabinoids, 75
Marin, Matthew G. Pharmacology of airway secretion, 273
Martin, Billy R. Cellular effects of cannabinoids, 45
Mast cells, calcium role, 363
Membrane
cellular effects of cannabinoids, 46, 67
lipophilicity of cannabinoids, 63
plasma, polyphosphoinositides, 241
potential, calcium antagonism and calcium entry blockade, 338
Metabolites
tetrahydrocannabinol
active metabolite theory, 31
excretion in urine and feces, 37
formed by livers (table), 37
found in man, 35
psychoactivity, 37
Methionine-enkephalin, characterization of beta-endorphin, 301
Miller, Robert. See Godfraind et al., 202
Monoterpenes, numbering system for metabolites, confusion, dibenzopyran method, 21
Muscle relaxants, health aspects of cannabis, 15
Muscle, skeletal
calcium entry blockers, 357
release of calcium, 365
Muscle, smooth
assays, opioid activities, 301
calcium entry blockers, 356
correlation between binding and pharmacological activity, 377
intestinal
calcium entry blockers, 357
density distribution histograms (fig.), 374
nonvascular
calcium antagonism and calcium entry blockade, 340
IC50 or IC90 values of calcium entry blockers (table), 341
pA2 values, intestine (table), 342
polyphosphoinositide cycle, 255, scheme showing synergism, 256
respiratory
calcium antagonism and calcium entry blockade, 343
Log IC50 values (table), 345
vascular, calcium entry blockers, 326
Myo-inositol polyphosphates
scheme showing suggested pathways, 248
structures (fig.), 247
Neonates, neuropharmacology of capsaicin, 185, 218
Nerves, neuropharmacology of capsaicin, 193
Nervous tissues
calcium antagonism and calcium entry blockers, 355
calcium antagonism and calcium entry blockade, 379
Neurochemistry, cannabinoid pharmacology, 161
Neurons, neuropharmacology of capsaicin, 193
Neuropharmacology, capsaicin, 179
Neurophysiology, cannabinoid pharmacology, 164
Neurotransmitters, beta-endorphin, related peptide hormones and, 291
Neutrophils, calcium role, 364
Nifedipine
concentration-effect curves, coronary artery (fig.), 386
effect on calcium-evoked contractions (fig.), 327
effect on coronary artery (fig.), 391
negative inotropic action (fig.), 380
protection from ischemia, 353
verapamil and, effect on slow action potentials (fig.), 349
Nitrendipine
binding, effect of protein concentration in assay medium (fig.), 373
calcium entry blockers effect on binding (fig.), 371
inhibition of binding by verapamil (fig.), 371
number of binding sites, membrane preparations (table), 368
Numbering systems
monoterpane and dibenzopyran
cannabinoids (fig.), 76
confusion, metabolites, 21
tetrahydrocannabinol (fig.), 22
Ohlsson, Agneta. See Agurell et al., 21
Opiate antagonists, beta-endorphin and peptides 1-6 (table), 302
Ouabain, effect on airway secretion, 285
Ovary, Leydig cells, 362
INDEX

structure, pharmacology of airway secretion, 275
Substance P
capsaicin
inflammation, 213
neuropeptide release, 198
neuropharmacology, 180
nonsystemic administration, 191
peptide specificity, 217
Synaptosomes, calcium entry blockers, 358

Taylor, John W., and Emil Thomas Kaiser. The structural characterization of δ-endorphin and related peptide hormones and neurotransmitters, 291
Tetrahydrocannabinol
acute and chronic effects of cannabis, 2
AUC values (fig.), 28
CBD and, effects on activity and rectal temperature, mice (table), 81
chemical structure of metabolites (table), 36
heterocyclic analogs (table), 141
kinetics (table), 25
log concentration of plasma and reported “high” (fig.), 29
metabolism, 33
miscellaneous THC’s, pharmacological effects (table), 136
natural and synthetic, pharmacological effects (table), 88
notations and symptoms in monkey (table), 79
other cannabinoids and, pharmacokinetics, emphasis on man, 21
pharmacokinetic parameters in man (fig.), 26
pharmacokinetics and distribution in animals, 31
plasma concentration and reported “high” (table), 29
plasma levels (fig.), 27
relative potency in rabbit model (table), 80
ring systems compared with benzopyran (fig.), 82
seizure-susceptible rabbit model, 79
structure-activity relationships in cannabinoids, 75
structure (fig.), 56
synthetic, pharmacological effects (table), 124
systemic availability (table), 27
time course of “high” versus plasma THC levels (fig.), 30
water-soluble derivatives (fig.), 60
Thyroid, parathyroid and, calcium antagonism and calcium entry blockade, 362
Tissue preparations, neuropharmacology of capsaicin, 196
Tolerance, cannabinoid pharmacology, 158
Trachea, calcium antagonism and calcium entry blockade, 346

Urine
excretion of tetrahydrocannabinol metabolites, 37
scheme for isolation of acidic metabolites (fig.), 34
structure of THC metabolites (fig.), 38

Uterus, calcium antagonism and calcium entry blockade, 347

Vas deferens, IC50 values, calcium entry blockers (table), 347
Veins, calcium antagonism and calcium entry blockade, 339
Verapamil
binding, 375
calcium channel receptor sites (fig.), 376
effect of diphenylpiperazines, 374
effect on cat papillary muscle (fig.), 351
inhibited nitrendipine binding (fig.), 371
negative inotropic action (fig.), 390
nifedipine and, effect on slow action potentials (fig.), 349
protection, 352

Wibo, Maurice. See Godfraind et al., 321
Widman, Marianne. See Agurell et al., 21